Association of pro-fibrinolytic receptor AnnexinA2 with tissue plasminogen activator/Inhibitor-1 in pre-eclampsia

Afr Health Sci. 2023 Mar;23(1):309-319. doi: 10.4314/ahs.v23i1.33.

Abstract

Background: The clinical manifestations of pre-eclampsia are related to placental anti-angiogenic factor alteration. These variations are mainly due to the alteration of plasminolytic components. The study aims to compare the expression of plasminolytic components in the placenta of women with and without pre-eclampsia.

Material and methods: The study included pregnant women with pre-eclampsia as PE group (n = 30) and without pre-eclampsia as a control group (n = 30). Placental bed biopsy tissues were collected. AnxA2, tPA, PAI-1 expression in the placental villous tissue was quantitatively evaluated using immunohistochemistry, western blot, and real time-PCR analysis.

Results: The results of the study showed a significant decrease in the expression of ANXA2 and increased expression of tPA and PAI-1 in PE group compared to control group (p<0.005). AnxA2 expression showed positive correlation with tPA (r=+0.895, p=0.002) and negative correlation with PAI-1(r=-0.905, p=0.020) in control group whereas in the PE group AnxA2 expression was negatively correlated with tPA ((r=-0.801, p=0.016) and PAI-1 (R=-0.831, P=0.010).

Conclusion: Decreased AnxA2 with increased expression of PAI-1 and tPA may be responsible for the altered fibrinolytic activity and play a significant role in pre-eclampsia pathogenesis.

Keywords: AnxA2; PAI-1; Pre-eclampsia; fibrinolysis; tPA.

MeSH terms

  • Annexin A2* / metabolism
  • Female
  • Fibrinolysis
  • Humans
  • Placenta
  • Plasminogen Activator Inhibitor 1* / metabolism
  • Pre-Eclampsia* / metabolism
  • Pregnancy
  • Tissue Plasminogen Activator* / metabolism

Substances

  • Plasminogen Activator Inhibitor 1
  • Tissue Plasminogen Activator
  • SERPINE1 protein, human
  • PLAT protein, human
  • ANXA2 protein, human
  • Annexin A2